Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 333

Similar articles for PubMed (Select 14624186)

1.
2.

Mr Jakubovski and Dr Bloch reply.

Jakubovski E, Bloch MH.

J Clin Psychiatry. 2015 Mar;76(3):327-8. doi: 10.4088/JCP.14lr09483a. No abstract available.

PMID:
25830452
3.

Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.

Seripa D, Pilotto A, Paroni G, Fontana A, D'Onofrio G, Gravina C, Urbano M, Cascavilla L, Paris F, Panza F, Padovani A, Pilotto A.

J Psychopharmacol. 2015 May;29(5):623-33. doi: 10.1177/0269881115578159. Epub 2015 Mar 31.

PMID:
25827644
4.

Serotonergic genes and depressive disorder in acute coronary syndrome: The Korean depression in ACS (K-DEPACS) study.

Kim JM, Stewart R, Kang HJ, Bae KY, Kim SW, Shin IS, Hong YJ, Ahn Y, Jeong MH, Park SW, Kim YH, Yoon JS.

Eur Neuropsychopharmacol. 2015 Jun;25(6):882-8. doi: 10.1016/j.euroneuro.2015.02.006. Epub 2015 Feb 28.

PMID:
25772786
5.

The "S" Allele of the Serotonin Transporter Is Not Associated with Major Depression in a Sample OF Veterans.

Cornelius JR, Haas GL, Goldstein G, Hanusa B, Walker JD, Fox LJ, Ferrell J.

Adv Genet Res. 2014;12:1-10.

6.

Longitudinal monitoring of the serotonin transporter gene expression to assess major depressive episode evolution.

Belzeaux R, Loundou A, Azorin JM, Naudin J, Ibrahim el C.

Neuropsychobiology. 2014;70(4):220-7. doi: 10.1159/000368120. Epub 2015 Jan 9.

PMID:
25592385
7.

Menopausal status could modulate the association between 5-HTTLPR and antidepressant efficacy in depressed women: a pilot study.

Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E.

Arch Womens Ment Health. 2014 Dec;17(6):569-73. doi: 10.1007/s00737-014-0464-1. Epub 2014 Sep 26.

PMID:
25257397
8.

Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism.

Bousman CA, Sarris J, Won ES, Chang HS, Singh A, Lee HY, Ham BJ, Tan CH, Lee MS, Ng CH.

J Clin Psychopharmacol. 2014 Oct;34(5):645-8. doi: 10.1097/JCP.0000000000000165.

PMID:
24943391
9.

Major depressive disorder and response to citalopram treatment in women attending menopause clinic.

Belső N, Kiss K, Rihmer Z, Tüzkő N, Tóth SJ, Paulin F.

Int J Psychiatry Clin Pract. 2003;7(4):269-72. doi: 10.1080/13651500310003183.

PMID:
24930413
10.

ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population.

Ozbey G, Yucel B, Taycan SE, Kan D, Bodur NE, Arslan T, Percin F, Yuksel N, Guzey C, Uluoglu C.

Pharmacol Rep. 2014 Apr;66(2):235-8. doi: 10.1016/j.pharep.2013.09.004. Epub 2014 Mar 2.

PMID:
24911075
11.

Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in Korean patients with major depression.

Kim YG, Chang HS, Won ES, Ham BJ, Lee MS.

Neuropsychobiology. 2014;69(4):210-9. doi: 10.1159/000362241. Epub 2014 May 27.

PMID:
24903772
12.

The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.

Tomita T, Yasui-Furukori N, Nakagami T, Tsuchimine S, Ishioka M, Kaneda A, Sugawara N, Kaneko S.

PLoS One. 2014 May 23;9(5):e98099. doi: 10.1371/journal.pone.0098099. eCollection 2014.

13.
14.

Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response.

Domschke K, Tidow N, Schwarte K, Deckert J, Lesch KP, Arolt V, Zwanzger P, Baune BT.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1167-76. doi: 10.1017/S146114571400039X. Epub 2014 Mar 28.

PMID:
24679990
15.

Prediction and structural equation model of sertraline treatment response in Japanese patients with major depressive disorder.

Nishioka G, Yashima H, Kiuchi Y, Nakamura S, Oyamada H, Ishii M, Kudo I.

Hum Psychopharmacol. 2013 Nov;28(6):576-85. doi: 10.1002/hup.2347. Epub 2013 Oct 7.

PMID:
24519691
16.

Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.

Gudayol-Ferré E, Herrera-Guzmán I, Camarena B, Cortés-Penagos C, Herrera-Abarca JE, Martínez-Medina P, Asbun-Bojalil J, Lira-Islas Y, Reyes-Ponce C, Guàrdia-Olmos J.

Hum Psychopharmacol. 2012 Nov;27(6):577-86.

PMID:
24446536
17.

Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder.

Sahraian S, Babashams M, Reza-Soltani P, Najmabadi H, Kahrizi K, Gorgani SH.

Iran J Psychiatry. 2013 Jun;8(2):86-91.

18.

Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults.

Garfield LD, Müller DJ, Kennedy JL, Mulsant BH, Reynolds CF 3rd, Teitelbaum SL, Civitelli R, Dixon D, Todorov AA, Lenze EJ.

World J Biol Psychiatry. 2014 Jul;15(5):404-10. doi: 10.3109/15622975.2013.832380. Epub 2013 Sep 30.

19.

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.

Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I.

Hum Psychopharmacol. 2013 Sep;28(5):516-22. doi: 10.1002/hup.2340.

PMID:
24014145
20.

SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.

Shiroma PR, Drews MS, Geske JR, Mrazek DA.

Am J Geriatr Psychiatry. 2014 Nov;22(11):1140-8. doi: 10.1016/j.jagp.2013.02.012. Epub 2013 Aug 20.

PMID:
23973251
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk